Table 1

Characteristics of patients with RA after ICI treatment for cancer

PatientsSex/age, yearsType of cancerICIDate of first ICI exposureDate of IrAEType of rheumatic IrAEIrAE response to treatmentAutoantibody results before ICIAutoantibody resultsTumour response
1F 55Squamous cell carcinoma of the vaginaNivolumabOctober 2015October 2015RAResolution with NSAIDsCCP: 61 U/mL
RF:negative
CCP:671 U/mL
RF:18 UI/mL
Progression death
2F 66Endometrial adenocarcinomaPembrolizumabMarch 2016April 2016RAResolution with prednisone 10 mg/dayNot availableCCP:233 U/mL
RF:180 UI/mL
Stable disease
3M 59Lung adenocarcinomaNivolumabMay 2016July 2016RAResolution with prednisone 10 mg/dayNot availableCCP:61 U/mL
RF:47 UI/mL
Good response
4F 56Metastatic melanomaPembrolizumabAugust 2015September 2015RANSAIDS and HCQ 400 mg/day:good responseCCP:22 U/mL
RF:negative
CCP:18 U/mL
RF<15 UI/mL
Stable disease
5M 80Metastatic melanomaNivolumabApril 2016April 2016RAPrednisone 15 mg/day and HCQ 200 mg/day:good responseCCP:negative
RF:not available
CCP:42 U/mL
RF<15 UI/mL
Stable disease
6M 68Lung adenocarcinomaNivolumabJune 2015July 2015RANSAID: no effect stopping nivolumab and MTX 10 mg/week:good responseNot availableCCP:>300 U/mL
RF:246 UI/mL
Stable disease
  • CCP, cyclic citrullinated peptide; F, female; HCQ, hydroxychloroquine; ICI, immune checkpoint inhibitor; IrAE, immune-related adverse event; M, male; MTX, methotrexate; NSAIDs, non-steroidal anti-Inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor.